These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Cellular immunotherapy as combination partners for the immune checkpoint blockade]. Rössig C Oncol Res Treat; 2014; 37 Suppl 4():14-5. PubMed ID: 25301192 [No Abstract] [Full Text] [Related]
4. Role of Local Radiation Therapy in Cancer Immunotherapy. Demaria S; Golden EB; Formenti SC JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858 [TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanisms of tumor and immune system interaction]. Berezhnoĭ AE; Gnuchev NV; Georgiev GP; Kozlov AM; Larin SS Vopr Onkol; 2008; 54(6):669-83. PubMed ID: 19241839 [No Abstract] [Full Text] [Related]
6. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? Furness AJ; Quezada SA; Peggs KS Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975 [No Abstract] [Full Text] [Related]
7. Cellular and humoral immune responses of cancer patients to defined tumor antigens. Jäger D; Jäger E; Bert F; Knuth A Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025 [No Abstract] [Full Text] [Related]
8. Radiation therapy to convert the tumor into an in situ vaccine. Formenti SC; Demaria S Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):879-80. PubMed ID: 23078897 [No Abstract] [Full Text] [Related]
9. Down-regulation of the antitumor immune response. North RJ Adv Cancer Res; 1985; 45():1-43. PubMed ID: 2936064 [No Abstract] [Full Text] [Related]
10. Introduction: Cancer Immunology Special Issue-Immunopathology. Kawakami Y Int Immunol; 2016 Aug; 28(8):371. PubMed ID: 27450690 [No Abstract] [Full Text] [Related]
11. Links between genetics and immunology: mutations and antigens. Ayyoub M Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414 [TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy: a treatment for the masses. Blattman JN; Greenberg PD Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469 [TBL] [Abstract][Full Text] [Related]
13. [Technological advances in immuno-oncology: from fundamental concepts to patient immunological monitoring]. Chouaib S; Echchakir H; Angevin E; Guerra N; Kosmatopoulos K; Caignard A; Lim A; Baron V; Ferradini L; Mami-Chouaib F Bull Cancer; 2001 Aug; 88(8):733-40. PubMed ID: 11578941 [TBL] [Abstract][Full Text] [Related]
14. Harnessing the power of Vδ2 cells in cancer immunotherapy. Fowler DW; Bodman-Smith MD Clin Exp Immunol; 2015 Apr; 180(1):1-10. PubMed ID: 25469879 [TBL] [Abstract][Full Text] [Related]
16. [Molecular targets for development of cancer immunotherapy]. Kawakami Y Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828 [No Abstract] [Full Text] [Related]
17. Targeting neoantigens to augment antitumour immunity. Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802 [TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines: pessimism in check. Mocellin S; Mandruzzato S; Bronte V; Marincola FM Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242 [No Abstract] [Full Text] [Related]
20. An introduction to tumour immunology. Keith J Mater Med Pol; 1984; 16(1):54-64. PubMed ID: 6394909 [No Abstract] [Full Text] [Related] [Next] [New Search]